Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00588809 · ClinicalTrials.gov registry record · Phase 2
Selumetinib in Treating Patients With Recurrent or Refractory Acute Myeloid Leukemia
A Phase 2 study, sponsored by National Cancer Institute (NCI).
- Completed
- Registry status
- Phase 2
- Development phase
- 47
- Enrollment target
NCT00588809: Completed Phase 2 study, sponsored by National Cancer Institute (NCI).
NCT00588809 is a Phase 2 study that has completed, run by National Cancer Institute (NCI). The registered enrollment target is 47 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00588809, a Phase 2 study, has completed, sponsored by National Cancer Institute (NCI).
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 47 participants
- Enrollment target
Study Summary
This phase II clinical trial is studying how well selumetinib works in treating patients with recurrent or refractory acute myeloid leukemia. Selumetinib may stop the growth of cancer by blocking some of the enzymes needed for cell growth
Interventions
- DRUG selumetinib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 47 participants |
| Start Date | 2007-12 |
| Est. Completion | 2012-12 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00588809
The ClinicalTrials.gov registry entry for NCT00588809 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 47 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is National Cancer Institute (NCI), which has 3,257 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which selumetinib is the first listed.
NCT00588809 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00588809 about?
NCT00588809 is a clinical study titled "Selumetinib in Treating Patients With Recurrent or Refractory Acute Myeloid Leukemia". This phase II clinical trial is studying how well selumetinib works in treating patients with recurrent or refractory acute myeloid leukemia. Selumetinib may stop the growth of cancer by blocking some of the enzymes needed for cell growth
What is the current status of trial NCT00588809?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 47 participants. The study started on 2007-12. Estimated completion is 2012-12.
What interventions are being tested in trial NCT00588809?
The interventions under investigation include: selumetinib (DRUG).
Who is sponsoring clinical trial NCT00588809?
This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.